|1.||Kim, Soo-Youl: 25 articles (06/2014 - 06/2002)|
|2.||Sollid, Ludvig M: 14 articles (12/2015 - 01/2010)|
|3.||Lindfors, Katri: 13 articles (03/2015 - 01/2008)|
|4.||Kaukinen, Katri: 13 articles (03/2015 - 01/2008)|
|5.||Khosla, Chaitan: 13 articles (10/2014 - 04/2005)|
|6.||Mäki, Markku: 10 articles (04/2014 - 01/2008)|
|7.||Kim, Dae-Seok: 9 articles (09/2013 - 11/2006)|
|8.||Iversen, Rasmus: 8 articles (12/2015 - 03/2012)|
|9.||Park, Kang-Seo: 7 articles (01/2011 - 06/2007)|
|10.||Stamnaes, Jorunn: 6 articles (06/2015 - 08/2010)|
11/07/2006 - "Recent studies have suggested that the transamidation activity of TGase-II is necessary for the survival of cancer cells confronted with different stresses and cellular insults. "
01/01/2015 - "Transglutaminase 2 in cancer."
06/01/2014 - "Gene expression analysis of BE and EACs were used to identify the cell surface marker transglutaminase 2 (TGM2) as overexpressed in cancer. "
08/01/2013 - "Anti-cancer effect of a quinoxaline derivative GK13 as a transglutaminase 2 inhibitor."
01/01/2013 - "Overexpression of Transglutaminase 2 (TG2), a multifunctional enzyme, in cancer cells impacts epithelial mesenchymal transition, growth, invasion and interactions with tumor microenvironment. "
|2.||Renal Cell Carcinoma (Grawitz Tumor)
01/01/2015 - "A few recent studies have demonstrated a possible role of transglutaminase 2 (TG2) in tumorigenesis or progression of renal cell carcinoma (RCC). "
01/01/2015 - "Transglutaminase 2 expression and its prognostic significance in clear cell renal cell carcinoma."
06/01/2014 - "Transglutaminase 2 (TGase 2) expression and glycolysis are increased in most renal cell carcinoma (RCC) cell lines compared to the HEK293 kidney cell line. "
09/01/2013 - "Transglutaminase 2 inhibition found to induce p53 mediated apoptosis in renal cell carcinoma."
05/01/2014 - "Transglutaminase 2 inhibitor abrogates renal cell carcinoma in xenograft models."
|3.||Wounds and Injuries (Trauma)
07/01/2011 - "Histology revealed that the most effective dose to improve wound repair and angiogenesis in diabetic mice was 30mg/kg. Furthermore HA injection (30mg/kg) improved the altered healing pattern in diabetic animals, increased skin remodeling proteins TGF-β and transglutaminase-II and restored the altered expression of cyclin B1/Cdc2 complex. "
05/31/2013 - "Here, using genome-wide transcriptional profiling, bioinformatics, and functional gene analysis, we identify a new axis of mosquito resistance to monoclonal Plasmodium falciparum infections that includes the AP-1 transcription factor Fos and the transglutaminase 2 (TGase2), a cross-linking enzyme with known roles in wound responses. "
03/01/2008 - "Mice were killed 3, 6, and 12 days after skin injury to measure vascular endothelial growth factor (VEGF) mRNA expression and protein synthesis, to assay angiogenesis and tissue remodeling through histological evaluation, and to study CD31, Angiopoietin-1 and Transglutaminase-II. Furthermore, we measured wound breaking strength at day 12. "
01/01/2015 - "However, it has recently been demonstrated that transglutaminase 2 (TG2) may also be involved in molecular mechanisms underlying inflammation. "
12/01/2014 - "Regulation of endothelial cell inflammation and lung polymorphonuclear lymphocyte infiltration by transglutaminase 2."
10/24/2014 - "The molecular mechanism of transglutaminase II (TGaseII)-mediated allergic inflammation remains largely unknown. "
01/01/2013 - "Transglutaminase 2 (TGase 2) promotes nuclear factor-κB (NF-κB) activity through depletion of the inhibitory subunit of NF-κB (I-κBα) via protein cross-linking, leading to resolution of inflammation. "
01/01/2011 - "CF airways are also characterized by chronic inflammation, pro-oxidative environment and increased transglutaminase 2 (TG2) levels. "
|5.||Huntington Disease (Huntington's Disease)
01/01/2014 - "Genetic deletion of transglutaminase 2 does not rescue the phenotypic deficits observed in R6/2 and zQ175 mouse models of Huntington's disease."
02/09/2012 - "Discovery and structure-activity relationship of potent and selective covalent inhibitors of transglutaminase 2 for Huntington's disease."
09/01/2010 - "The article by McConoughey et al in the current issue of EMBO Molecular Medicine examines the contribution of transglutaminase 2 (TG2) to Huntington's disease (HD) pathogenesis. "
09/01/2010 - "Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease."
12/13/2012 - "SAR Development of Lysine-Based Irreversible Inhibitors of Transglutaminase 2 for Huntington's Disease."
|1.||Proteins (Proteins, Gene)
|3.||Messenger RNA (mRNA)
|5.||70-kDa Ribosomal Protein S6 Kinases (Ribosomal Protein S6 Kinases, 70 kDa)
|8.||Protein Phosphatase 2 (Protein Phosphatase 2A)
|10.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|1.||Drug Therapy (Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)